Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update

NEXT STORY
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
PREV STORY
G1 Therapeutics Provides Fourth Quarter and Full-Year 2019 Corporate and Financial Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

author_avatar
NASDAQ Market News

Biocartis’ Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Biocartis Group NV ('Biocartis' or the 'Company'), an innovative molecular diagnostics company (Euronext Brussels: ...

author_avatar
NASDAQ Market News

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

author_avatar
NASDAQ Market News